GSA Capital Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

GSA Capital Partners’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,768	Closed	-$217K	–	1616
2020 Q4	$217K	Sell	3,768 -2,931	-44%	-$171K	0.04%	936
2020 Q3	$398K	Buy	+6,699	New	+$598K	0.07%	544
2019 Q3	–	Sell	-113	Closed	-$34K	–	1812
2019 Q2	$34K	Sell	113 -60	-35%	-$25K	﹤0.01%	1387
2019 Q1	$78K	Buy	+173	New	+$75.7K	0.01%	1349
2018 Q4	–	Sell	-307	Closed	-$279K	–	1857
2018 Q3	$279K	Sell	307 -801	-72%	-$529K	0.02%	1357
2018 Q2	$650K	Buy	+1,108	New	+$723K	0.03%	1015

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

GSA Capital Partners's HTGM Position: Q1 2021 in Review

GSA Capital Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2021, closing a stake of 3,768 shares — an estimated $217K sold.

GSA Capital Partners first reported a position in HTGM in Q2 2018 and held it in 6 quarters. The position peaked at $650K in Q2 2018. 24 funds tracked by Wall St. Rank hold HTGM as of Q1 2021.

GSA Capital Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
GSA Capital Partners sold 3,768 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2021, an estimated $217K.
GSA Capital Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
GSA Capital Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $650K in Q2 2018.
24 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.